
Global Neuraminidase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Neuraminidase Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, Daiichi Sankyo and BioCryst, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Neuraminidase Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Neuraminidase Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Neuraminidase Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neuraminidase Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neuraminidase Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neuraminidase Inhibitor sales, projected growth trends, production technology, application and end-user industry.
Neuraminidase Inhibitor Segment by Company
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
Daiichi Sankyo
BioCryst
Neuraminidase Inhibitor Segment by Type
Oseltamivir
Laninamivir
Peramivir
Zanamivir
Neuraminidase Inhibitor Segment by Application
Hospital Pharmacies
Drug Stores
Retail Stores
Others
Neuraminidase Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neuraminidase Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
According to APO Research, The global Neuraminidase Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Neuraminidase Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, Daiichi Sankyo and BioCryst, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Neuraminidase Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Neuraminidase Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Neuraminidase Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neuraminidase Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neuraminidase Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neuraminidase Inhibitor sales, projected growth trends, production technology, application and end-user industry.
Neuraminidase Inhibitor Segment by Company
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
Daiichi Sankyo
BioCryst
Neuraminidase Inhibitor Segment by Type
Oseltamivir
Laninamivir
Peramivir
Zanamivir
Neuraminidase Inhibitor Segment by Application
Hospital Pharmacies
Drug Stores
Retail Stores
Others
Neuraminidase Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neuraminidase Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Table of Contents
186 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neuraminidase Inhibitor Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Neuraminidase Inhibitor Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Neuraminidase Inhibitor Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Neuraminidase Inhibitor Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Neuraminidase Inhibitor Market Dynamics
- 2.1 Neuraminidase Inhibitor Industry Trends
- 2.2 Neuraminidase Inhibitor Industry Drivers
- 2.3 Neuraminidase Inhibitor Industry Opportunities and Challenges
- 2.4 Neuraminidase Inhibitor Industry Restraints
- 3 Neuraminidase Inhibitor Market by Manufacturers
- 3.1 Global Neuraminidase Inhibitor Revenue by Manufacturers (2020-2025)
- 3.2 Global Neuraminidase Inhibitor Sales by Manufacturers (2020-2025)
- 3.3 Global Neuraminidase Inhibitor Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Neuraminidase Inhibitor Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Neuraminidase Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Neuraminidase Inhibitor Manufacturers, Product Type & Application
- 3.7 Global Neuraminidase Inhibitor Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Neuraminidase Inhibitor Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Neuraminidase Inhibitor Players Market Share by Revenue in 2024
- 3.8.3 2024 Neuraminidase Inhibitor Tier 1, Tier 2, and Tier 3
- 4 Neuraminidase Inhibitor Market by Type
- 4.1 Neuraminidase Inhibitor Type Introduction
- 4.1.1 Oseltamivir
- 4.1.2 Laninamivir
- 4.1.3 Peramivir
- 4.1.4 Zanamivir
- 4.2 Global Neuraminidase Inhibitor Sales by Type
- 4.2.1 Global Neuraminidase Inhibitor Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Neuraminidase Inhibitor Sales by Type (2020-2031)
- 4.2.3 Global Neuraminidase Inhibitor Sales Market Share by Type (2020-2031)
- 4.3 Global Neuraminidase Inhibitor Revenue by Type
- 4.3.1 Global Neuraminidase Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Neuraminidase Inhibitor Revenue by Type (2020-2031)
- 4.3.3 Global Neuraminidase Inhibitor Revenue Market Share by Type (2020-2031)
- 5 Neuraminidase Inhibitor Market by Application
- 5.1 Neuraminidase Inhibitor Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Drug Stores
- 5.1.3 Retail Stores
- 5.1.4 Others
- 5.2 Global Neuraminidase Inhibitor Sales by Application
- 5.2.1 Global Neuraminidase Inhibitor Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Neuraminidase Inhibitor Sales by Application (2020-2031)
- 5.2.3 Global Neuraminidase Inhibitor Sales Market Share by Application (2020-2031)
- 5.3 Global Neuraminidase Inhibitor Revenue by Application
- 5.3.1 Global Neuraminidase Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Neuraminidase Inhibitor Revenue by Application (2020-2031)
- 5.3.3 Global Neuraminidase Inhibitor Revenue Market Share by Application (2020-2031)
- 6 Global Neuraminidase Inhibitor Sales by Region
- 6.1 Global Neuraminidase Inhibitor Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Neuraminidase Inhibitor Sales by Region (2020-2031)
- 6.2.1 Global Neuraminidase Inhibitor Sales by Region (2020-2025)
- 6.2.2 Global Neuraminidase Inhibitor Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Neuraminidase Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Neuraminidase Inhibitor Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Neuraminidase Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Neuraminidase Inhibitor Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Neuraminidase Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Neuraminidase Inhibitor Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Neuraminidase Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Neuraminidase Inhibitor Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Neuraminidase Inhibitor Revenue by Region
- 7.1 Global Neuraminidase Inhibitor Revenue by Region
- 7.1.1 Global Neuraminidase Inhibitor Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Neuraminidase Inhibitor Revenue by Region (2020-2025)
- 7.1.3 Global Neuraminidase Inhibitor Revenue by Region (2026-2031)
- 7.1.4 Global Neuraminidase Inhibitor Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Neuraminidase Inhibitor Revenue (2020-2031)
- 7.2.2 North America Neuraminidase Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Neuraminidase Inhibitor Revenue (2020-2031)
- 7.3.2 Europe Neuraminidase Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Neuraminidase Inhibitor Revenue (2020-2031)
- 7.4.2 Asia-Pacific Neuraminidase Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Neuraminidase Inhibitor Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Neuraminidase Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 GlaxoSmithKline
- 8.1.1 GlaxoSmithKline Comapny Information
- 8.1.2 GlaxoSmithKline Business Overview
- 8.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio
- 8.1.5 GlaxoSmithKline Recent Developments
- 8.2 Gilead Sciences
- 8.2.1 Gilead Sciences Comapny Information
- 8.2.2 Gilead Sciences Business Overview
- 8.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Gilead Sciences Neuraminidase Inhibitor Product Portfolio
- 8.2.5 Gilead Sciences Recent Developments
- 8.3 F. Hoffman-La Roche
- 8.3.1 F. Hoffman-La Roche Comapny Information
- 8.3.2 F. Hoffman-La Roche Business Overview
- 8.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio
- 8.3.5 F. Hoffman-La Roche Recent Developments
- 8.4 Daiichi Sankyo
- 8.4.1 Daiichi Sankyo Comapny Information
- 8.4.2 Daiichi Sankyo Business Overview
- 8.4.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio
- 8.4.5 Daiichi Sankyo Recent Developments
- 8.5 BioCryst
- 8.5.1 BioCryst Comapny Information
- 8.5.2 BioCryst Business Overview
- 8.5.3 BioCryst Neuraminidase Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 BioCryst Neuraminidase Inhibitor Product Portfolio
- 8.5.5 BioCryst Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Neuraminidase Inhibitor Value Chain Analysis
- 9.1.1 Neuraminidase Inhibitor Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neuraminidase Inhibitor Production Mode & Process
- 9.2 Neuraminidase Inhibitor Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neuraminidase Inhibitor Distributors
- 9.2.3 Neuraminidase Inhibitor Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.